Abstract: The invention provides a capacitive energy storage device comprising: at least one porous film infiltrated with an electrolyte; and one or more pairs of separated electrodes disposed on top of a first surface of the porous film, each electrode comprising a capacitive electrode material in ionic communication with the underlying porous film, wherein the electrolyte provides ionic communication between the separated electrodes via the internal porosity of the porous film.

Abstract: The present invention relates to compositions, methods and kits for the treatment of fibrosis. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment of cardiac fibrosis. The invention provides a method of treating fibrosis in an individual comprising administering an AT2R selective agonist, thereby treating fibrosis.

Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

Abstract: The present invention relates generally to the field of immunomodulation. Taught herein is an agent for inhibiting immunostimulation mediated by a Toll-like receptor useful in the treatment of viral and microbial pathogenesis, diseases involving elements of autoimmunity and inflammation as well as cancer. The agent antagonizes disulfide bond formation between C98 and C475 of Toll-like receptor 7 (TLR7) thereby preventing TLR7 activation. Pharmaceutical compositions are also enabled herein.

Abstract: The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.

Abstract: An apparatus for performing bioelectric stimulation, the apparatus comprising: a stimulation unit; a measurement unit comprising an amplifier; first and second stimulation electrodes operable to apply electrical signals to tissue of a patient; first and second measurement electrodes operable to receive first and second measurement signals from the tissue of the patient; wherein the stimulation unit is configured to deliver a first stimulation signal to the first stimulation electrode and a second stimulation signal to the second stimulation electrode; wherein the first signal and the second signal are mirrored about a biasing voltage, the biasing voltage set in dependence of the dynamic range of the amplifier.

Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

Abstract: The present disclosure relates generally, but not exclusively, to compounds and their use in therapy, to compositions and agents comprising said compounds, to methods of treatment using said compounds, and their use in the manufacture of medicaments. The disclosure further relates to inhibitors of IRAP and their use in the treatment or prevention of Alzheimer's disease and the treatment and prevention of memory and cognitive disorders.

Abstract: The present invention generally relates to methods and compositions for the treatment of overweight or obese individuals. In particular, the invention relates to reducing adiposity of an overweight or obese individual. The present invention provides a method for reducing adiposity or treating obesity in an individual, the method comprising inhibiting TCPTP and/or PTP1B in the hypothalamus of the individual, thereby reducing adiposity or treating obesity in the individual.

Abstract: This invention relates to polypeptides, including variants of interleukin-37 (IL-37), and related therapeutics and compositions. The invention also relates to the use of the polypeptides and compositions in methods of treating inflammatory diseases or conditions. The present invention provides a monomeric anti-inflammatory polypeptide comprising an amino acid sequence of an IL-37 monomer, the amino acid sequence having a mutation or modification for preventing the anti-inflammatory peptide from forming a homodimer.

Abstract: Dirac semimetals, methods for modulating charge carrying density and/or band gap in a Dirac semimetal, devices including a Dirac semimetal layer, and methods for forming a Dirac semimetal layer on a substrate are described.

Abstract: The present invention relates to antimicrobial polymyxin derivative compounds and their uses, and in particular to peptide polymyxin antibiotics which may be used in the treatment of bacterial infections such as Gram negative bacterial infections, particularly those caused by multidrug-resistant (MDR) Gram negative bacterial infections.

Abstract: A method of producing Sulfur cathodes for Li—S batteries utilising dry mixing of constituents (sulphur, carbon and binder) or semi-dry mixing. The resultant structure binds the neighbouring particles without covering them, i.e. by attaching a few parts of a particle to other neighbouring particles provides a solution for the successful cycling of thick and ultra-thick sulfur cathodes. Such an approach provides a robust thick cathode where particles are strongly bonded with minimal surface coverage with the polymer providing sufficient room to expand during lithiation. Bridging bonds are formed within the cathodes.

Abstract: An isolated or purified AON for modifying pre-mRNA splicing in the Receptor for Advanced Glycation End-products (RAGE) to modulate splicing of the RAGE gene transcript or part thereof is provided.

Abstract: Expression of proteolytically active, high molecular weight ADAM10 protease is relatively increased in tumour cells that also express the putative tumour stem cell marker CD133. A recombinant humanized antibody or antibody fragment based on 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.

Abstract: A diagnostic device for analysing properties of an analyte in a sample liquid including: a distribution zone having at least two hydrophilic layers placed one on top of the other, wherein one layer is a top layer (12) and the other is a bottom layer (13); and a detection zone located under the distribution zone, the detection zone having a detection layer (14), wherein: the top layer has one or more openings (15) through which the sample liquid is introduced into the device; the bottom layer having one or more openings (16) connecting the distribution zone to the detection zone; the bottom layer also having a means by which the sample liquid is distributed from the top layer's opening to the detection layer through the bottom layer's opening; and a visual indication results on the detection layer when the sample liquid comes into contact with the detection layer.

Abstract: Closed-loop transcranial stimulation and monitoring is disclosed that includes generating a stimulation signal having a set of first oscillation parameters; applying the stimulation signal transcranially to a patient; monitoring the stimulation signal as applied to the patient; receiving a brain activity signal from the patient; generating a feedback signal based on the monitored stimulation signal as applied to the patient; and generating a modified activity signal by subtracting the feedback signal from the brain activity signal; determining one or more second oscillation parameters of the modified activity signal; and adjusting the set of first oscillation parameters of the stimulation signal based on the one or more second oscillation parameters of the modified activity signal. Closed-loop transcranial stimulation and monitoring is also disclosed in which the patient is engaged in a cognitive task.

Abstract: The present disclosure relates generally to the methods of treatment of mammalian subjects by an enhanced cell-based therapeutic approach in order to facilitate tissue and neuronal repair, regeneration and/or reparation. Medicaments useful in the treatment of mammalian subjects and methods of production of the medicaments are also encompassed by the present disclosure.

Abstract: The invention relates to IL-21, to antibodies and related fragments thereof for binding to IL-21, to production of said antibodies and fragments and to use of said antibodies and fragments for detection and therapy of various conditions, in particular inflammation, infection and oncology.

Abstract: The present invention relates to methods for treating or preventing or delaying the progression or onset of autoimmune disease, comprising the use of dietary metabolites.